Accelerate therapeutic development by identifying and validating drug candidates efficiently through advanced in vitro platforms and custom approaches.
Our discovery services accelerate your therapeutic development, guiding you to lead candidate selection with precision and efficiency. We specialise in complex in vitro pharmacology assessments using our advanced instrumentation and bespoke approaches. Pre-established disease models and high-quality, reproducible data support early-stage decision-making. Driven by innovative biology, we create tailored assay systems to kick-start your discovery pipeline. Partner with us to achieve your project goals.
Target Identification and Validation
Antibody Discovery & Development
Lead Selection
We collaborate to understand underlying biology and develop tailored approaches for disease target validation. Using high-content methods like multiparameter flow cytometry and immunohistochemistry, we assess target expression in fresh and frozen tissues and cells from healthy donors and patient populations, cryopreserved PBMCs, recallable blood donors, and a vast collection of immortalised cell lines. Our world-class team of immune cell experts applies their expertise to hypothesis testing of new targets using in vitro immunology models. We tailor services to address the underlying biology, employing complex models built with our expertise in T cells, Tregs, NK cells, DCs, B cells, neutrophils, macrophages, and PBMC/whole blood.
We use surrogate molecules and engineered approaches to explore target function and gain clarity. Custom-designed signalling reporter cells and knockout engineered cell systems help delineate converging signalling pathways and achieve greater resolution. Partner with us to advance your therapeutic development with precision and efficiency.
We collaborate to understand underlying biology and develop tailored approaches for disease target validation. Using high-content methods like multiparameter flow cytometry and immunohistochemistry, we assess target expression in fresh and frozen tissues and cells from healthy donors and patient populations, cryopreserved PBMCs, recallable blood donors, and a vast collection of immortalised cell lines. Our world-class team of immune cell experts applies their expertise to hypothesis testing of new targets using in vitro immunology models. We tailor services to address the underlying biology, employing complex models built with our expertise in T cells, Tregs, NK cells, DCs, B cells, neutrophils, macrophages, and PBMC/whole blood.
We use surrogate molecules and engineered approaches to explore target function and gain clarity. Custom-designed signalling reporter cells and knockout engineered cell systems help delineate converging signalling pathways and achieve greater resolution. Partner with us to advance your therapeutic development with precision and efficiency.
AVS Bio offers design-driven lead antibody generation services, tailored to target insights and lead antibody requirements leveraging its comprehensive suite of services spanning the entire antibody discovery and engineering lifecycle:
High-quality tools are the foundation of successful antibody programs. AVS Bio generates critical reagents including recombinant proteins, engineered cell lines, and assay-ready materials to support discovery and downstream testing. AVS Bio works closely with clients to ensure tools accurately reflect native biology and intended applications. Rigorous validation ensures reliability, reproducibility, and performance in functional assays. These robust tools accelerate decision-making and reduce development risk.
AVS Bio’s immunization services are designed to generate broad and high-affinity antibody responses against various targets, including challenging ones. AVS Bio employs optimized immunization strategies tailored to antigen type, format, and therapeutic objectives. They support a range of species and immunization protocols to maximize diversity and immune response quality. Careful monitoring of immune response profiles guides strategic decision-making. This disciplined approach enhances the discovery of high-quality antibody candidates.
AVS Bio delivers fully customized antibody discovery programs designed around each client’s specific target biology and therapeutic goals. Using a combination of in vivo and in vitro platforms, AVS Bio generates highly diverse antibody repertoires to accelerate identification of suitable lead candidates. Their integrated screening strategies prioritize affinity, specificity, and biological relevance from the earliest stages. Advanced assay platforms enable rapid hit identification and data-driven candidate selection. From antigen design through lead nomination, AVS Bio provides a seamless and collaborative discovery experience.
AVS Bio provides in-depth antibody characterization to ensure selection of the most promising leads. They evaluate binding affinity, specificity, epitope recognition, and functional activity using robust biochemical and cell-based assays. Advanced analytical platforms generate high-quality data to support confident candidate progression. Comparative analyses help prioritize molecules with optimal biological performance. AVS Bio’s comprehensive characterization framework reduces downstream risk and strengthens development readiness.
Early assessment of developability is critical for successful antibody advancement. AVS Bio evaluates key attributes including stability, aggregation propensity, solubility, and manufacturability. Their profiling workflows identify potential liabilities before significant time and resources are invested. Data-driven insights inform candidate selection and risk mitigation strategies. By integrating developability assessment early, AVS Bio helps streamline the path toward clinical readiness.
AVS Bio applies advanced engineering strategies to enhance antibody performance and therapeutic potential. They support affinity maturation, humanization, de-risking and format engineering tailored to program goals. Rational design and screening approaches enable improvement of potency, stability, and manufacturability. These optimisation capabilities transform promising leads into development-ready candidates.
AVS Bio offers reliable recombinant protein and antibody production services to support discovery and preclinical development. Using optimized mammalian expression systems, high-quality proteins tailored to client specifications are delivered. Scalable purification workflows ensure purity, integrity, and batch-to-batch consistency. Each product undergoes stringent quality control to confirm identity and functionality. These efficient production capabilities enable rapid turnaround and reliable material supply.
AVS Bio develops stable, high-performing mammalian cell lines for target or antibody expression and long-term production. Their cell line development strategies focus on productivity, stability, and scalability to support research and preclinical supply. Optimized vector design and selection workflows are employed to identify high-yield clones efficiently. Comprehensive characterization ensures consistent performance across passages. These tailored expression systems provide a strong foundation for downstream manufacturing and scale-up.
With extensive experience in bioanalytical assay design, immunology, cellular and molecular biology, we create platform screening systems tailored to your needs. Our multi-tier lead selection process focuses on binding, functionality and disease translation. We utilise ELISA, SPR, flow cytometry, kinetic analysis and immune cell functional assays to select and validate leads with confidence.
Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.
